Overview

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Status:
Terminated
Trial end date:
2018-10-11
Target enrollment:
Participant gender:
Summary
The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Miami
Collaborator:
Genentech, Inc.
Treatments:
Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab
Vinblastine
Vinorelbine